Is Xencor, Inc. (XNCR) a Buy, Sell, or Hold?
Xencor, Inc.
NASDAQ:XNCR
$14.98 USD
$0.03 (0.2%)
- Volume
- 451.28K
- Average Volume
- 829.26K
- Market Capitalization
- $1.11B
- P/E Ratio
- -6.54
- Dividend Yield
- 0.00%
- Price Target
- $27.00
- Year High
- $18.69
- Year Low
- $6.92
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $6.57
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Bassil I. Dahiyat |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | XNCR |
| CUSIP | 98401F105 |
| CIK | 0001326732 |
| Web | https://www.xencor.com |
| Phone | 626 305 5900 |
| Currency | USD |
| Employees | 260 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.34 |
| Payout Ratio | 0.00 |
| Current Ratio | 6.57 |
| Quick Ratio | 6.57 |
| Cash Ratio | 0.19 |
Sales & Book Value
| Annual Sales | $125.58M |
| Price / Sales | 11.41 |
| Cash Flow | -2.51 |
| Price / Cash Flow | -5.88 |
| Price / Book | 2.19 |
Price Target and Rating
| Average Stock Price Forecast | $27.00 |
| High Stock Price Forecast | $27.00 |
| Low Stock Price Forecast | $27.00 |
| Forecast Upside/Downside | -44.52% |
| Consensus Rating | Strong Sell |
| Rating Score(0-5) | 1 |
| Research Coverage | 28 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-1.24 |
| Trailing P/E Ratio | -6.54 |
| PEG Ratio | 0.09 |
| P/E Growth | 0.09 |
| Net Income | $-91.92M |
| Net Margin | -177.10% |
| Pretax Margin | -174.61% |
| Return on Equity | -28.77% |
| Return on Assets | -23.40% |
Financials Score
| AltmanZ Score | 1.41 |
| Piotroski Score | 1.00 |
| Working Capital | 409.4M |
| Total Assets | 736.85M |
| Ebit | -142.04M |
| Market Cap | 1.11B |
| Total Liabilities | 221.21M |
Poll Results
About Xencor, Inc. (NASDAQ:XNCR) Stock
Xencor Inc., a biopharmaceutical firm headquartered in Monrovia, California, and established in 1997, operates as a clinical-stage entity. Its central mission involves the discovery and sophisticated engineering of monoclonal antibody and cytokine therapeutics, primarily aimed at treating patients afflicted with cancer and autoimmune disorders. The company is associated with several notable therapies currently in use, such as Sotrovimab, which targets the SARS-CoV-2 virus; Ultomiris, prescribed for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi, indicated for individuals with relapsed or refractory diffuse large B-cell lymphoma. Xencor maintains a robust and diverse pipeline of drug candidates advancing through various clinical trial stages. In onco ... logy, this includes Plamotamab, a tumor-targeted antibody, currently undergoing Phase I trials for non-Hodgkin lymphoma; Vudalimab, a bispecific antibody in Phase II for metastatic castration-resistant prostate cancer and other solid tumor types; and Tidutamab, also in Phase II for neuroendocrine tumors. Further cancer-focused programs comprise XmAb306, XmAb104, and XmAb841, all in Phase I for selected solid tumors; AMG 509, in Phase I for prostate cancer; XmAb819, being developed for renal cell carcinoma; and a program involving Novartis XmAb. In the infectious disease arena, Xencor is progressing VIR-3434 through Phase II for hepatitis B virus infection; VIR-2482 in Phase 1/2 for influenza A; VIR-7832 in a Phase 1b/2a trial for mild-to-moderate COVID-19; and is involved in the Phase 2/3 NIH ACTIV-2 trial for COVID-19 with BMS-986414 + BMS-986413. Beyond these, the company is developing XmAb564, a Phase I candidate for autoimmune diseases; Obexelimab, also for autoimmune conditions; AIMab7195, designed to reduce IgE levels for allergic responses; and Xpro1595, an experimental treatment for Alzheimer's disease, mild cognitive impairment, and depression. Xencor also holds a licensing agreement with Caris Life Sciences.
Xencor: Bullish On Their Increasingly In-House Pipeline
2026-07-14 16:01:56
Xencor, Inc. is shifting from licensing optionality toward a broader portfolio of in-house assets across oncology and immunology. The upcoming XmAb819 and XmAb541 dose-selection data will soon clarify whether XNCR's oncology assets can become pivotal candidates. XmAb942 is probably their most important catalyst over the long term. The earlier-stage autoimmune programs should help sustain XNCR's valuation in the near term.
2026-05-18 09:00:00
MindWalk Holdings Corp. (NASDAQ: HYFT) today released a systematic report identifying over 20 discovery-originated drug candidates with documented origins in a
Xencor, Inc. (XNCR) Presents at Bank of America Global Healthcare Conference 2026 Transcript
2026-05-13 03:40:47
Xencor, Inc. (XNCR) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Xencor (XNCR) Reports Q1 Loss, Lags Revenue Estimates
2026-05-06 18:11:06
Xencor (XNCR) came out with a quarterly loss of $1.71 per share versus the Zacks Consensus Estimate of a loss of $0.65. This compares to a loss of $0.66 per share a year ago.
Xencor Reports First Quarter 2026 Financial Results
2026-05-06 16:01:00
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today reported financial results for the first quarter ended March 31, 2026. “Xencor continues to execute across our wholly owned clinical pipeline, with significant progress in both oncology and autoimmune disease. We look forward to presenting expansion cohort data from our Phase 1 study of XmAb819 for t.
2026-05-05 18:41:19
Xencor, Inc. (XNCR) Discusses Phase I Results for XmAb942 and Preclinical Data for XmAb412 Transcript
Xencor to Host Webcast to Discuss XmAb942 and XmAb412 Data Presentations at DDW
2026-05-04 08:01:00
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today reported final results from the Phase 1 study of XmAb942, a novel, potential best-in-class, long-acting anti-TL1A antibody for the treatment of inflammatory bowel disease (IBD). The results are being presented today at Digestive Disease Week® (DDW), being held in Chicago. Tomorrow, the company will a.
Frequently Asked Questions
-
What is the current Xencor, Inc. (XNCR) stock price?
-
Xencor, Inc.(NASDAQ:XNCR) stock price is $14.98 in the last trading session. During the trading session, XNCR stock reached the peak price of $18.69 while $6.92 was the lowest point it dropped to. The percentage change in XNCR stock occurred in the recent session was 0.2% while the dollar amount for the price change in XNCR stock was $0.03.
-
XNCR's industry and sector of operation?
-
The NASDAQ listed XNCR is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of XNCR?
-
Mark Osterman | Senior Vice President of Clinical Development (Autoimmune)
Bart Jan Cornelissen | Senior Vice President & Chief Financial Officer
John R. Desjarlais | Executive Vice President of Research & Chief Scientific Officer
Bassil I. Dahiyat | Co-Founder, Chief Executive Officer, President & Director
Celia E. Eckert | Senior Vice President, General Counsel & Corporate Secretary -
How many employees does XNCR have?
-
Number of XNCR employees currently stands at 260. XNCR operates from 111 West Lemon Avenue, Pasadena, CA 91016, US.
-
Link for XNCR official website?
-
Official Website of XNCR is: https://www.xencor.com
-
How do I contact XNCR?
-
XNCR could be contacted at phone #626 305 5900 and can also be accessed through its website. XNCR operates from 111 West Lemon Avenue, Pasadena, CA 91016, US.
-
How many shares of XNCR are traded daily?
-
The average number of XNCR shares traded daily for last 3 months was 829.26K.
-
What is the market cap of XNCR currently?
-
The market value of XNCR currently stands at $1.11B with its latest stock price at $14.98